scholarly journals 745-5 Increased Monday Incidence of Life Threatening Ventricular Arrhythmias: Experience with a Third Generation Implantable Defibrillator

1995 ◽  
Vol 25 (2) ◽  
pp. 188A ◽  
Author(s):  
Robert W. Peters ◽  
Steve McQuillan ◽  
Susan A. Kaye ◽  
Michael R. Gold
2007 ◽  
Vol 28 (14) ◽  
pp. 1746-1749 ◽  
Author(s):  
Jeffrey S. Healey ◽  
Al P. Hallstrom ◽  
Karl-Heinz Kuck ◽  
Girish Nair ◽  
Eleanor P. Schron ◽  
...  

Medicina ◽  
2021 ◽  
Vol 57 (3) ◽  
pp. 205
Author(s):  
Nicola Tarantino ◽  
Domenico G. Della Rocca ◽  
Nicole S. De Leon De La Cruz ◽  
Eric D. Manheimer ◽  
Michele Magnocavallo ◽  
...  

A recent surveillance analysis indicates that cardiac arrest/death occurs in ≈1:50,000 professional or semi-professional athletes, and the most common cause is attributable to life-threatening ventricular arrhythmias (VAs). It is critically important to diagnose any inherited/acquired cardiac disease, including coronary artery disease, since it frequently represents the arrhythmogenic substrate in a substantial part of the athletes presenting with major VAs. New insights indicate that athletes develop a specific electro-anatomical remodeling, with peculiar anatomic distribution and VAs patterns. However, because of the scarcity of clinical data concerning the natural history of VAs in sports performers, there are no dedicated recommendations for VA ablation. The treatment remains at the mercy of several individual factors, including the type of VA, the athlete’s age, and the operator’s expertise. With the present review, we aimed to illustrate the prevalence, electrocardiographic (ECG) features, and imaging correlations of the most common VAs in athletes, focusing on etiology, outcomes, and sports eligibility after catheter ablation.


2017 ◽  
Vol 36 (4) ◽  
pp. S432 ◽  
Author(s):  
J.G. Jungschleger ◽  
M.M. Mydin ◽  
A. Woods ◽  
M. Urban ◽  
N. Robinson ◽  
...  

2020 ◽  
Vol 22 (12) ◽  
Author(s):  
Lisa D. Wilsbacher

Abstract Purpose of Review Dilated cardiomyopathy (DCM) frequently involves an underlying genetic etiology, but the clinical approach for genetic diagnosis and application of results in clinical practice can be complex. Recent Findings International sequence databases described the landscape of genetic variability across populations, which informed guidelines for the interpretation of DCM gene variants. New evidence indicates that loss-of-function mutations in filamin C (FLNC) contribute to DCM and portend high risk of ventricular arrhythmia. Summary A clinical framework aids in referring patients for DCM genetic testing and applying results to patient care. Results of genetic testing can change medical management, particularly in a subset of genes that increase risk for life-threatening ventricular arrhythmias, and can influence decisions for defibrillator therapy. Clinical screening and cascade genetic testing of family members should be diligently pursued to identify those at risk of developing DCM.


1995 ◽  
Vol 28 ◽  
pp. 71-73
Author(s):  
Labros A. Karagounis ◽  
Kenneth M. Stein ◽  
Tami Bair ◽  
Derrick Albright ◽  
Jeffrey L. Anderson

Sign in / Sign up

Export Citation Format

Share Document